Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial

Plain-language guide to PMID 36271471 (2023): double-blind randomized controlled trial study of Parathyroid Hormone (PTH 1-84).

Key Facts

PMID: 36271471
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Year: 2023
Study type: Randomized Controlled Trial
Authors: Khan AA et al. (20 authors)
DOI: 10.1002/jbmr.4726

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

Conventional therapy for hypoparathyroidism consisting of active vitamin D and calcium aims to alleviate hypocalcemia but fails to restore normal parathyroid hormone (PTH) physiology.

PTH replacement therapy is the ideal physiologic treatment for hypoparathyroidism.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Parathyroid Hormone (PTH 1-84).

A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.

The timeline in the abstract includes 4 weeks.

What Was Measured

Other outcomes of interest included health-related quality of life measured by the 36-Item Short Form Survey (SF-36), hypoparathyroidism-related symptoms, functioning, and well-being measured by the Hypoparathyroidism Patient Experience Scale (HPES), and urinary calcium excretion.

PubMed files the paper under topics including Parathyroid Hormone, Calcium, Quality of Life, Hypoparathyroidism, Vitamin D, Hormone Replacement Therapy and Calcium, Dietary.

Author keywords: CLINICAL TRIALS, DISORDERS OF CALCIUM/PHOSPHATE, PARATHYROID-RELATED DISORDERS and PTH/VIT D/FGF23.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) over 4 weeks.

The publication is from 2023 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.

Our Notes on the Compound

Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.

Parathyroid Hormone (PTH 1-84) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.